InsiderTrades.com logo
Election warning coming true…
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.
Karen A. Dawes net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Karen Dawes Biography and Net Worth

Director of Vaccitech
Karen Dawes has held senior executive and commercial positions at key biopharmaceutical companies and was responsible for the successful launch and marketing of a number of drugs.
Karen is President and founder of Knowledgeable Decisions, LLC, a biopharma pharmaceutical consulting firm focusing on development and commercial/corporate strategy. She previously served as Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group, Senior Vice President, Global Strategic Marketing for Wyeth LLC, and Vice President, Chief Commercial Officer for Genetics Institute, Inc.. Karen began her pharmaceutical career at Pfizer, Inc. where she held numerous positions including Vice President, Marketing for the Pratt Division. She is Chairperson of the Board of Directors of Repligen Corporation and serves as a Board Director for Medicenna Therapeutics, PaxMedica Therapeutics, and Medicines 360. She received her M.B.A. from Harvard University and her B.A. and M.A. in English from Simmons College.

What is Karen A. Dawes' net worth?

The estimated net worth of Karen A. Dawes is at least $84,763.46 as of February 27th, 2024. Ms. Dawes owns 87,367 shares of Vaccitech stock worth more than $84,763 as of November 17th. This net worth estimate does not reflect any other assets that Ms. Dawes may own. Learn More about Karen A. Dawes' net worth.

How do I contact Karen A. Dawes?

The corporate mailing address for Ms. Dawes and other Vaccitech executives is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. Vaccitech can also be reached via phone at 44-18-6581-8808 and via email at [email protected].. Learn More on Karen A. Dawes' contact information.

Has Karen A. Dawes been buying or selling shares of Vaccitech?

Karen A. Dawes has not been actively trading shares of Vaccitech during the last ninety days. Most recently, on Tuesday, May 4th, Karen A. Dawes bought 1,700 shares of Vaccitech stock. The stock was acquired at an average cost of $17.00 per share, with a total value of $28,900.00. Following the completion of the transaction, the director now directly owns 1,700 shares of the company's stock, valued at $28,900. Learn More on Karen A. Dawes' trading history.

Who are Vaccitech's active insiders?

Vaccitech's insider roster includes Karen Dawes (Director), Christopher Ellis (COO), Graham Griffiths (Insider), and Robin Wright (Director). Learn More on Vaccitech's active insiders.

Karen A. Dawes Insider Trading History at Vaccitech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2021Buy1,700$17.00$28,900.001,700View SEC Filing Icon  
See Full Table

Karen A. Dawes Buying and Selling Activity at Vaccitech

This chart shows Karen A Dawes's buying and selling at Vaccitech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaccitech Company Overview

Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $0.97
Low: $0.88
High: $1.38

50 Day Range

MA: $1.57
Low: $1.19
High: $5.00

2 Week Range

Now: $0.97
Low: $1.64
High: $5.10

Volume

263,301 shs

Average Volume

244,643 shs

Market Capitalization

$37.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Election warning coming true…
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.